GSK Reportedly in Talks to Acquire Cancer Biotech Nuvalent for Over $9 Billion

UK drugmaker GSK is reportedly in discussions to purchase cancer biotechnology firm Nuvalent for more than $9 billion, a deal that would rank among GSK's largest acquisitions.

9 Jun, 01:03 — 9 Jun, 01:03

Post Share

Sources

Showing 1 of 1 sources

FTVery High2h ago

GSK in talks to buy cancer biotech Nuvalent for more than $9bn

A deal will rank as one of UK drugmaker’s biggest as biotech M&A activity has enjoyed an upswing this year

Read full article →

PERSPECTA

PERSPECTA

GSK Reportedly in Talks to Acquire Cancer Biotech Nuvalent for Over $9 Billion

Sources

GSK in talks to buy cancer biotech Nuvalent for more than $9bn

Related Stories

Amazon's First Customer Receipt Goes Viral, Bezos and Musk React

Investigation Launched into Overharvesting of Pen Shells in Sorsogon Bay

EU Plans to Boost Technological Sovereignty

ADMIE Holdings Prepares for €530 Million Capital Increase

PERSPECTA